Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

SOUTH SAN FRANCISCO, CA, USA I May 6, 2025 I IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and ...

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

It is a part of a wide development programme, being evaluated as both monotherapy and as conjunction therapy for small cell lung cancer (SCLC), NSCLC, and for gastrointestinal, bladder and breast ...

In 2022, Roche reported that tiragolumab missed the mark in a pair of phase 3 lung cancer studies – SKYSCRAPER-1 in NSCLC and SKYSCRAPER-2 in extensive-stage small-cell lung cancer (ES-SCLC ...

After a setback in a trial of Imfinzi in early non-small cell lung cancer (NSCLC) last year, AstraZeneca has clawed back some ground with a positive result in small-cell lung cancer (SCLC), a less ...

Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors ...

SCLC is an aggressive cancer which spreads at an early stage ... flat cells that line the airways. Surgery for NSCLC has proven to be effective, with National Cancer Registration and Analysis Service ...

Once non-small-cell lung cancer (NSCLC) spreads far and wide, treating it is kind of a balancing act. A cure isn't likely, but you can slow it down. So you aim to relieve your symptoms and improve ...